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Background: Recently, natural mutation of Tyrosine kinase 2 (Tyk2) gene has been shown to determine suscepti-
bility to murine virus-induced diabetes. In addition, a previous human genome-wide study suggested the type 1
diabetes (T1D) susceptibility region to be 19p13, where the human TYK2 gene is located (19p13.2).
Methods: Polymorphisms of TYK2 gene at the promoter region and exons were studied among 331 healthy
controls, and 302 patients with T1D and 314 with type 2 diabetes (T2D) in the Japanese.
Findings: A TYK2 promoter haplotype with multiple genetic polymorphisms, which are in complete linkage
disequilibrium, named TYK2 promoter variant, presenting decreased promoter activity, is associated with an
increased risk of not only T1D (odds ratio (OR), 2.4; 95% conﬁdence interval (CI), 1.2 to 4.6; P= 0.01), but also
T2D (OR, 2.1; 95% CI, 1.1 to 4.1; P=0.03). The risk is high in patients with T1D associatedwith ﬂu-like syndrome
at diabetes onset and also those without anti-glutamic acid decarboxylase autoantibody.
Interpretation: The TYK2 promoter variant is associatedwith an overall risk for diabetes, serving a good candidate
as a virus-induced diabetes susceptibility gene in humans.
Funding:Ministry of Education, Culture, Sports, Science and Technology and of Health, Labor andWelfare of Japan.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).ence and Technology, Graduate
12-8582, Japan.
afuchi).
. This is an open access article under1. Introduction
Diabetes mellitus is on the rise worldwide, and is associated with
improvement in socioeconomic conditions, increasing wealth, higher
caloric and fat intake and lower physical activity (Scully, 2012;the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Characteristics of patients with T1D and T2D, and healthy controls.
Characteristics Type 1 diabetesa Type 2 diabetes Healthy controls
Number 302 314 331
Age (years) (range) 40.7 ± 17.3
(7–83)
61.8 ± 11.8
(17–91)
43.4 ± 12.7
(18–71)
Men (%) 37.4 51.3 53.5
HbA1c (%)b 8.9 ± 2.3 7.9 ± 1.6 5.2 ± 0.7
BMI (kg/m2) 21.8 ± 3.1 23.2 ± 3.6 22.0 ± 3.3
Age at diabetes onset
(range)
27.8 ± 17.9
(0–73)
NAc NA
Anti-GAD Abd positive
(%)
58.6 NTe NT
Values are means ± standard deviation.
T1D, type 1 diabetes; T2D, type 2 diabetes.
a Patients with T1D were diagnosed as they have fasting serum c-peptide level below
0.5 ng/ml.
b HbA1c (%) was expressed as National Glycohemoglobin Standardization Program
(NGSP) value.
c NA: not available.
d Anti-GAD ab: anti-glutamic acid decarboxylase antibody (≥1.5 U/ml).
e NT: not tested.
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sociation of environmental factors such as toxins and viruses with
diabetes (Jonietz, 2012). However, the role of these environmental
factors in the development of diabetes is not yet fully understood.
Virus infection has long been considered to be a possible cause of type
1 diabetes (T1D), as suggested by many clinical and experimental obser-
vations (Taylor, 2013; Coppieters et al., 2012). Itwas reported that several
viruses including coxsackie B virus, cytomegalovirus, varicella-zoster
virus, and rubella virus, were found in the pancreatic islets in patients
with severe fatal viral infections (Jenson et al., 1980), suggesting that
systemic severe viral infections could lead to the pancreatic β-cell
damage. Virus-induced diabetes is a more complex disease than pre-
viously thought, and is ascribed to diverse mechanisms that may lead
to damage of the pancreatic β-cells (Coppieters et al., 2012). These
mechanisms include direct virolysis, local inﬂammatory response, and
triggering of autoimmunity against β-cells (Coppieters et al., 2012).
However, the precise mechanisms of pancreatic β-cell damage
caused by viral infections remain to be determined, and host factors
that control virus-induced diabetes have not been elucidated.
Accumulating evidence strongly suggests the contribution of entero-
viruses, which belong to the picornavirus group, to the elevated risk of
diabetes (Tauriainen et al., 2011; Oikarinen et al., 2011; Tanaka et al.,
2009). Since resistance to picornavirus infection has been shown to be
dependent on innate immunity (Ida-Hosonuma et al., 2005; Takeuchi
and Akira, 2009), the molecules regulating innate immune responses
are candidates for determining susceptibility to virus-induced diabetes
(Kounoue et al., 2008; Nagafuchi et al., 2013). These include interferon
itself, interferon production and interferon receptor-mediated sig-
naling pathway-associated molecules including pattern recognition
receptors (PRR) directed against pathogen-associated molecular
patterns (PAMPs) such as toll-like receptors (TLR) and intracellular
helicases such as retinoic acid-inducible gene I (RIG-I) and interferon
induced with the helicase C domain I (IFIH1) or melanocyte differen-
tiation antigen (MDA)-5 (MDA-5/IFIH1) (Takeuchi and Akira, 2009).
Interferon-regulatory factors and interferon receptor-associated down-
streammolecules including JAK1, TYK2, STAT1 and STAT2 are also im-
portant with respect to serving as resistance against viral infections
(Nagafuchi et al., 2013) (Supplementary Fig. 1). However, the exact
host factors that confer susceptibility to virus-induced diabetes
remain uncertain.
Since innate immunity plays a signiﬁcant role in the protection
against experimental encephalomyocarditis (EMC) virus (a picornavi-
rus)-induced diabetes (Kounoue et al., 2008), it is suggested that intact
operation of the interferon signaling pathway may be important for
resistance against virus-induced diabetes. It should be noted that this
experimental virus-induced diabetes in mice is an excellent model as
rapid onset T1D including fulminant type, but not autoimmune diabetes
(Imagawa et al., 2000; Nagafuchi et al., 2013). A separate study from our
group presented experimental evidence that the Tyk2 gene, an interfer-
on receptor signaling pathway molecule, was responsible for encepha-
lomyocarditis (EMC) virus-induced diabetes susceptibility in mice
(Izumi et al., 2015). Highly virus-induced diabetes-susceptible strains
such as SJL and SWR mice possessing a mutated Tyk2 gene, which is
associated with reduced expression of Tyk2 gene in pancreatic β-cells,
were prone to the development of diabetes caused by the diabetogenic
strain of EMC-D virus (Izumi et al., 2015). Interestingly, a human
genome-wide study suggested the T1D susceptibility region to be chro-
mosome 19p13 (Mein et al., 1998), where the TYK2 gene was located
(19p13.2) (Firmbach-Kraft et al., 1990). However, the exact responsible
gene has not yet been identiﬁed.
These observations suggest that the human TYK2 gene may be
associated with the risk for T1D and also confer a possible link with
virus-induced diabetes susceptibility in humans. We thus examined
the association of TYK2 gene polymorphisms with T1D and type 2
diabetes (T2D), focusing on association with ﬂu-like syndrome at
diabetes onset.2. Methods
2.1. Subjects
We studied 947 Japanese patients and controls. Those include 302
patients with T1D, 314 patients with T2D and 331 healthy controls.
Among the 302 patients with T1D, 73 patients were associated
with ﬂu-like syndrome at the onset. Clinical proﬁles of the Japanese
patients with T1D or T2D, and the healthy controls are presented in
Table 1.
Patients were designated as T1D if fasting C-peptidewas b0.5 ng/ml
and they were in an insulin-dependent condition (IDDM), or as T2D if
fasting blood glucose levels were higher than 126 mg/dl and HbA1c
levels exceeded 6.5% with non-insulin-dependent status (NIDDM).
Patients with T1D were also grouped according to their age at onset,
as 0 to 19 (0–19), 20 to 39 (20–39), 40 to 59 (50–59), and 60 to 79
(60–79) years old. The studywas conducted according to the guidelines
for human study and was approved by the ethical committee of the
Kyushu University, Graduate School of Medical Sciences (No. 433-00).
Written informed consent was obtained from all subjects including
T1D, T2D and healthy controls involved in this study.
2.2. Genotyping of TYK2 Gene
Genotyping had been performed to detect 25 exons and the puta-
tive promoter region, 1.3 kb upstream of start codon, of the TYK2
gene. TYK2 sequence reference was NCBI Reference Sequence: NG_
007872.1. PCR ampliﬁcation of the target genes, followed by the di-
rect sequencing of the ampliﬁed gene, was conducted. A list of
primers used to detect the polymorphisms of the TYK2 gene is pre-
sented in Supplementary Table 1.
2.3. TYK2 Promoter Variant Gene Analysis
To identify the TYK2 promoter variant, we used PCR analysis follow-
ed by direct sequencing to identify−930G N A and−929 T N A at the
promoter region, using the following primer sets: F:5′-GAA TCG CTT
GAA TCC GGG AG-3′, and R:5′-ACC CTT CTT CTG TGC CAC AC-3′. Thus,
we present TYK2 promoter genotypes of wild type and variant type as
GT and AA, respectively.
2.4. Statistical Analysis
The genotype distribution between the cases and controls was sta-
tistically assessed by χ2 test. Odds ratio (OR) and 95% conﬁdence
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done using Stata version 10 (Stata Corporation, College Station, Texas).
3. Results
3.1. Polymorphisms of Human TYK2 Gene
We ﬁrst screened human TYK2 gene polymorphisms in 22 patients
with T1D associated with ﬂu-like syndrome, suggestive of possible viral
infection, by PCR ampliﬁcation followed by direct sequencing. We
found seven polymorphisms: −930G N A, −929T N A and
−104A N C at the promoter region from transcription start point at
exon 1; 1A N G, 62G N A and 63G N A at exon 1, which is an untrans-
lated region; and 15597G/T at exon 8 with an amino acid substitu-
tion from valine to phenylalanine (V326F) (Fig. 1).
Among them, 1A N G (rs17000728), 62G N A (rs17000728) and
63G N A (rs2304258) at exon 1, and 15597G/T (V326F) at exon 8
(rs2304256) have been already identiﬁed by the 1000 Genomes Pro-
ject that included the Japanese population (The 1000 Genomes
Project Consortium, 2010, 2012). Because the polymorphisms at
the promoter region and exon 1 were in complete linkage disequilib-
rium in all 7 patients (Table 2), the haplotype was named TYK2 pro-
moter variant.
3.2. Signiﬁcance of TYK2 Promoter Variant
We ﬁrst studied the association of the missense change at exon 8
with diabetes. We compared 244 patients with T1D, 255 patients with
T2D and 254 healthy controls, and found no measurable difference in
the genotype frequency between diabetic patients and healthy controls
(Supplementary Table 2).Promoter Region 
-930 G>A -929 T>A -104 A>C 1
Wild 
AAGTGG GCAAA AC
Hetero 
AA        
GT
GG GC
A 
AA AC 
AA C 
Homo 
AAAAGG GCCAA AC
Positions of mutations were described from transcription start point at Exon
Fig. 1. Polymorphisms of TYK2 gene 22 patients with type 1 diabetes associatedwith ﬂu-like syn
exon 1.We further compared the prevalence of TYK2 promoter variant;
GT/AA and AA combined, and compared with wild type GT in 302
patients with T1D, 314 patients with T2D and 331 healthy controls
(Table 1). Among them, 73 T1D patients had a ﬂu-like syndrome at
diabetes onset. The frequency of the TYK2 promoter variant was signiﬁ-
cantly higher in patients with T1D (odds ratio (OR), 2.4; 95% conﬁdence
interval (CI), 1.2 to 4.6; P=0.01), and also in patients with T2D (OR, 2.1;
95% CI, 1.1 to 4.1; P= 0.03), compared with healthy controls (Table 3).
Thus, the TYK2 promoter variant was more frequent in all patients with
diabetes compared with healthy controls (OR, 2.3; 95% CI, 1.2 to 4.1;
P= 0.009) (Table 3). The TYK2 promoter variant was associated with a
more evident increase in risk of T1D patients associated with a ﬂu-like
syndrome (OR, 3.6; 95% CI, 1.5 to 8.5; P= 0.005) (Table 3). In addition,
the TYK2 promoter variant was signiﬁcantly more frequent among T1D
patients without anti-glutamic acid decarboxylase autoantibody (GAD)
(OR, 3.3; 95% CI, 1.6 to 7.2; P = 0.002), but not among anti-GAD
autoantibody-positive patients (OR, 1.7; 95% CI, 0.8 to 3.9; P = 0.21)
(Table 3).
It is thus suggested that the risk for diabetes conferred by the TYK2
promoter variant is distinct from autoimmunity against pancreatic β-
cells. We grouped TID associated with ﬂu-like syndrome and analyzed
the age at onset and anti-GAD antibody positivity, in association with
TYK2 promoter variant. There was no statistical signiﬁcance in the age
at onset (P = 0.16), but has signiﬁcantly increased frequency in anti-
GAD antibody negative T1D (OR, 5.0; 95% CI, 1.9 to 13.2; P = 0.0005)
(Supplementary Table 3), consistent with the observation of all T1D
patients. There was no gender difference in the frequency of TYK2 pro-
moter variant, among patients with T1D (male, 13/113; 11.5%, female,
16/189; 8.5%; P = 0.39), and also T2D (male, 14/161; 8.7%, female,
13/153; 8.5%; P = 0.95). In the age-speciﬁc analysis on subjects with
T1D,we found that the TYK2 promoter variant haplotypewas associated
with a higher risk for diabetes in younger people aged 0 to 19 years (OR,Exon 1 Exon 8 
 A>G 62 G>A 63 G>A 15597 G>T  (V326F) 
AAG AAGGGT CAGTC
A 
AG AA 
GG 
GT CA
G 
TC
G AA T 
GAG AAAAGT CATTC
1.  
drome at the onset. Positions of mutationswere described from transcription start point at
Table 2
Screening of TYK2 gene polymorphism in 22 patients with T1D associated with ﬂu-like syndrome at diabetes onset.
Case no. Age at the onset Sex SNPs at promoter region SNPs at exon 1 SNP at exon 8
−930G N A −929G N A −104A N C 1A N G 62G N A 63G N A 15597G N T
1 49 M
2 47 F Hetero Hetero Hetero Hetero Hetero Hetero
3 61 F Hetero Hetero Hetero Hetero Hetero Hetero
4 31 F
5 36 F Hetero
6 40 F Hetero
7 59 F Hetero
8 9 M Homo Homo Homo Homo Homo Homo
9 10 M
10 43 M Hetero Hetero Hetero Hetero Hetero Hetero
11 52 M Hetero Hetero Hetero Hetero Hetero Hetero Hetero
12 53 M Hetero
13 34 F Hetero Hetero Hetero Hetero Hetero Hetero
14 24 F Hetero
15 62 F Hetero
16 35 M Hetero Hetero Hetero Hetero Hetero Hetero Hetero
17 25 M
18 30 M
19 48 F
20 40 F
21 24 M Hetero
22 27 M Homo
T1D, type 1 diabetes.
Hetero: heterozygous polymorphism.
Homo: homozygous polymorphism.
747S. Nagafuchi et al. / EBioMedicine 2 (2015) 744–7492.4; 95% CI, 1.1 to 5.4; P=0.04) and 20 to 39 years (OR, 3.1; 95% CI, 1.4
to 6.9; P= 0.006), but not in older patients aged 40–59 years (OR, 1.6;
95% CI, 0.5 to 5.1; P= 0.62) or 60–79 years (OR, 1.2; 95% CI, 0.1 to 9.5;
P= 0.68) (Table 4).
Thus, the TYK2 promoter variant is associated with an increased risk
of T1D with a younger age of onset.
In the age group of 20–39, we found no difference in the age at onset
(P= 0.17), however, those with variant type are more associated with
anti-GAD negative people (OR, 5.1; 95% CI, 1.9 to 13.6; P=0.0003), and
also with ﬂu-like syndrome at the onset (OR, 4.8; 95% CI, 1.4 to 15.49;
P = 0.022) (Supplementary Table 3), consistent with the observation
in all T1D. Since obesity is an important risk for endocrinological disor-
ders (Dwivedi et al., 2012), we also analyzed the association between
BMI and TYK2 promoter variant in T2D. There was no difference in
BMI between T2D with TYK2 promoter wild type gene and variant
type (P = 0.12) (Supplementary Table 4). In addition, there was in-
creased TYK2 promoter variant rate at statistical signiﬁcance only in
non-obese T2D with less than 26 BMI (OR, 2.4; 95% CI, 1.2 to 4.8; P =
0.01), but not obese T2D with more than 26 BMI (OR, 0.8; 95% CI, 0.2
to 3.7; P = 1.0) (Supplementary Table 4), suggesting that obesity is
not likely involved in the increased risk associated with TYK2 promoter
variant in T2D.
3.3. Promoter Activity of the TYK2 Promoter Variant
To determine the function of the TYK2 promoter variant gene, we
performed a luciferase assay, and found that the variant type promoter
showed signiﬁcantly reduced promoter activity (82.29 ± 0.03%;
P b 0.001) (Supplementary Fig. 2A). Similarly, there was a slight de-
crease in the interferon-induced expressions of TYK2 gene (mean ±
SD of the relative expression; 0.59±0.21) in peripheral bloodmononu-
clear cells derived from diabetic patients with TYK2 promoter variant
(n = 14), compared with those (0.71 ± 0.28) of patients with the
wild type TYK2 gene (n = 17), while there was a mild increase in the
interferon-induced expressions of JAK1 gene (mean± SD of the relative
expression; before stimulation; 0.74 ± 0.19 to 0.82 ± 0.17 after stimu-
lation) in peripheral blood mononuclear cells derived from diabetic
patients with TYK2 promoter variant (n = 14), compared with those
(before stimulation; 0.82 ± 0.21 to 0.84 ± 0.21 after stimulation) ofpatients with the wild type TYK2 gene (n = 17) (Supplementary
Fig. 2B). The expression levels of ISGs, including PKR, OAS andMxA, in-
duced by interferon stimulation in patients with TYK2 promoter variant
were also lower than those of patients withwild type ISGs (Supplemen-
tary Fig. 2C), which did not reach statistical signiﬁcance (all: P N 0.05).
These results suggest that the increased risk of developing diabetes con-
ferred by the TYK2 promoter variant may be due to reduced TYK2 pro-
moter activity accompanied by the decreased expression of the TYK2
gene and ISGs, while increased expression level of JAK1 gene on IFN
stimulation in patients with TYK2 promoter variant may play a comple-
mentary role for thedeteriorated TYK2 gene expression tomaintain ISGs
responses. Further investigation is required to clarify the inﬂuence of
TYK2 promoter variant on cytokine responses in humans.
4. Discussion
In the present study, based on our experimental evidence that the
natural susceptibility gene to EMC virus-induced diabetes was Tyk2 in
mice (Izumi et al., 2015), we could extend those observations to
humans, with a TYK2 promoter variant which is associated with an
overall increased risk for diabetes in Japanese subjects, particularly in
patients with T1D associated with ﬂu-like syndrome at onset. In addi-
tion, a genome wide study had identiﬁed the T1D susceptibility-
associated region as 19p13 (Mein et al., 1998), where the TYK2 gene is
located (19p13.2)(Firmbach-Kraft et al., 1990). All these observations
taken together indicate that the TYK2 gene might be regarded as a
good candidate for the virus-induced diabetes susceptibility gene in
humans. Surprisingly, the TYK2 gene promoter region variant was
more frequent not only in subjects with T1D but also those with T2D.
If TYK2 promoter variant is actually associated with increased suscepti-
bility to virus-induced diabetes, these results suggest that viral infection
may be one of the risk factors for developing T2D, which is consistent
with the concept that the accumulation of environmental insults will
lead to clinical diabetes (Toniolo et al., 1980). Since TYK2 gene is also
associated with other several cytokine signals including IL-6, IL-10, IL-
12, and IL-23 (Strobl et al., 2011; Casanova et al., 2012; O'Shea et al.,
2013), suggesting that deteriorated cytokine responses that can modu-
late immune/inﬂammatory reactions, alone or in combination, due to
TYK2 promoter variant, may also play a role to serve an increased risk
Table 3
TYK2 promoter variant in patients with T1D and T2D, and healthy controls.
Positive (≥1.5 U/ml)
(n = 177)
Negative(<1.5 U/ml)
(n = 125)
No (%) No (%) ORc (95% CId) No (%) OR (95% CI) No (%) OR (95% CI) No (%) OR (95% CI) No (%) OR (95% CI)
GT 317 (95.8) 1.00b 1.00b 164 (92.7) 1.00b 1.00b 287 (91.4) 1.00b
GT/AA 14 (4.2) 25 (8.0)
3.6 (1.5−8.5) 1.7 (0.8−3.9) 3.3 (1.6−7.2) 2.1 (1.1−4.1)
AA 0 (0.0) 2 (0.6)
P-valuee 0.01 0.005 0.21 0.002 0.03
T1D
Anti-GAD antibody
All (n = 302)
Flu-like syndromea
associated (n = 73)
T2D (n = 314)
Genotype
Healthy control
(n = 331)
12 (6.8)
1 (0.6)
109 (87.2)
0 (0)
16 (12.8)
273 (90.4)
1 (0.3)
28 (9.3)
2.4 (1.2−4.6)
63 (86.3)
1 (1.4)
9 (12.3)
T1D, type 1 diabetes; T2D, type 2 diabetes.
a
Symptoms of ﬂu-like syndrome include fever, chills, sore throat, muscle and joint aches, poor appetite, diarrhea, cough, and fatigue, suggestive of certain viral infections.
b
Referent.
c
OR, odds ratio.
d
CI, conﬁdence interval.
e
Heterozygous (GT/AA) and homozygous (AA) variant genotypes combined (TYK2promoter variant) versus homozygouswild genotype (GT) between the cases and healthy controlswas
statistically assessed by χ2 test.
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between inborn errors or polymorphisms of TYK2 gene and awide spec-
trum of autoimmune diseases, inﬂammatory diseases, tumors, and obe-
sity (Strobl et al., 2011; Casanova et al., 2012; O'Shea et al., 2013;
Derecka et al., 2012). Therefore unknown factors associated with the
TYK2 promoter variant other than viral infection may also contribute
to increase the risk for diabetes. At least, as indicated in our study,
TYK2 promoter variant in T2D was associated with non-obese patients
but not with obesity.
Interestingly, TYK2 promoter variant was associated with a signiﬁ-
cantly higher susceptibility to diabetes in anti-GAD antibody-negative
patients (OR, 3.3; P = 0.002), of which observation is consistent with
Tyk2genemutation dependentmurine virus-induced diabetes that sim-
ulates non-autoimmune rapid onset and fulminant T1D without auto-
antibody production (Imagawa et al., 2000; Nagafuchi et al., 2013;
Izumi et al., 2015). It was reported that the Tyk2 gene played an impor-
tant role not only in the interferon signaling pathway but also in the Th1
type immune response-associated IL-12-dependent signaling pathway
(Shimoda et al., 2000). It was also reported that autoimmunity to
pancreatic β-cells, associated with the development of T1D, wasmainly
dependent on Th1 type immune response (Haskins and Cooke, 2011).
These observations suggest that the human TYK2 gene promoter variant
may reduce the risk for the development of Th1 type-dependent
autoimmune reactivity to the pancreatic β-cells. In addition, if TYK2
promoter variant confer risk for the development of diabetes due toTable 4
TYK2 promoter variant genotypes in patients with T1D, with stratiﬁcation by the age of
onset.
Age at onset T1D (n = 302) ORa (95% CIb) P-valuec
Wild Hetero Homo
0–19 104 (90.4%) 10 (8.7%) 1 (0.9%) 2.4 (1.1–5.4) 0.04
20–39 94 (87.9%) 13 (12.1%) 0 (0%) 3.1 (1.4–6.9) 0.006
40–59 56 (93.3%) 4 (6.7%) 0 (0%) 1.6 (0.5–5.1) 0.62
60–79 19 (95.0%) 1 (5.0%) 0 (0%) 1.2 (0.1–9.5) 0.68
T1D, type 1 diabetes.
a OR, odds ratio.
b CI, conﬁdence interval.
c Heterozygous and homozygous variant genotypes combined (TYK2 promoter variant)
versus homozygous wild genotype in comparison with healthy controls (see Table 3).increased susceptibility to viral-infection, possible induction of autoim-
munity against pancreaticβ-cells triggered by viral infections,which is a
well-documented hypothesis (Fairweather and Rose, 2002; Stene et al.,
2010), was not a major pathogenic mechanism, in TYK2 promoter
variant-associated susceptibility to type 1 diabetes. Since these data
have been obtained in the Japanese population, less prone to T1D than
other ethnic groups, the possible role of TYK2 promoter variant needs
to be veriﬁed in different populations.
In human cases the situation is highly different from that in experi-
mental animals where mice have been infected with a virus and it is
possible to prove that infection is causing diabetes, however, accumula-
tion of circumstantial evidence to identify the putative virus-induced
susceptibility gene in humans is important. It was reported that poly-
morphisms of the IFIH1 gene, which is an intracellular pathogen recog-
nition receptor for picornavirus including enteroviruses, operating as an
inducer of interferon production (Takeuchi and Akira, 2009), is asso-
ciated with risk or resistance for the T1D, serving possible virus-
induced susceptibility gene in humans (Smyth et al., 2006; Nejentsev
et al., 2009). Since the outcome of virus-induced diabetes is inﬂuenced
by many factors including viral diabetogenicity and host susceptibility,
the discovery of other risk genes associatedwith virus-induced diabetes
in addition to IFIH1 and TYK2 genes is both possible and feasible. Unfor-
tunately, at present, there is no appropriate assay system to prove the
diabetogenicity of the virus infective for humans, fulﬁlling ‘Koch’s
postulate (Tabrah, 2011). Mouse models that are simulative of human
virus-induced diabetes, with higher virus-induced diabetes susceptibil-
ity for use as an in vivo assay system to evaluate the diabetogenic poten-
tial of the possible viral agents that are infectious for humans. Mouse
strains endowed with high susceptibility to picornavirus-induced dia-
betes may be used as in vivo models to evaluate the diabetogenicity of
candidate human viruses.Author Contributions
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